Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss
- PMID: 34312676
- PMCID: PMC8446930
- DOI: 10.1093/jac/dkab232
Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss
Abstract
Background: Macrolides are widely prescribed antibiotics for many different indications. However, there are concerns about adverse effects such as ototoxicity.
Objectives: To investigate whether macrolide use is associated with tinnitus and hearing loss in the general population.
Methods: Cross-sectional (n = 4286) and longitudinal (n = 636) analyses were performed within the population-based Rotterdam Study. We investigated with multivariable logistic regression models the association between macrolides and tinnitus, and with multivariable linear regression models the association between macrolides and two different hearing thresholds (both ears, averaged over 0.25, 0.5, 1, 2, 4 and 8 kHz and 2, 4 and 8 kHz). Both regression models were adjusted for age, sex, systolic blood pressure, alcohol, smoking, BMI, diabetes, education level, estimated glomerular filtration rate and other ototoxic or tinnitus-generating drugs. Cumulative exposure to macrolides was categorized according to the number of dispensed DDDs and duration of action.
Results: In the fully adjusted model, ever use of macrolides was associated with a 25% higher likelihood of prevalent tinnitus (OR = 1.25; 95% CI 1.07-1.46). This association was more prominent in participants with a cumulative dose of more than 14 DDDs and among users of intermediate- or long-acting macrolides. Macrolide use in between both assessments was associated with more than a 2-fold increased risk on incident tinnitus. No general association between macrolides and hearing loss was observed. A borderline significant higher hearing threshold in very recent users (≤3 weeks) was found.
Conclusions: Macrolide use was significantly associated with both prevalent and incident tinnitus. Macrolide-associated tinnitus was likely cumulative dose-dependent.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Figures
Similar articles
-
Increased risk of hearing loss associated with macrolide use: a systematic review and meta-analysis.Sci Rep. 2024 Jan 2;14(1):183. doi: 10.1038/s41598-023-50774-1. Sci Rep. 2024. PMID: 38167873 Free PMC article.
-
Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.J Cancer Surviv. 2023 Feb;17(1):27-39. doi: 10.1007/s11764-022-01313-w. Epub 2023 Jan 13. J Cancer Surviv. 2023. PMID: 36637632
-
Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a large prospective study.J Am Acad Audiol. 2010 Jun;21(6):409-17. doi: 10.3766/jaaa.21.6.6. J Am Acad Audiol. 2010. PMID: 20701838 Free PMC article.
-
Macrolide-associated sensorineural hearing loss: A systematic review.Laryngoscope. 2018 Jan;128(1):228-236. doi: 10.1002/lary.26799. Epub 2017 Aug 3. Laryngoscope. 2018. PMID: 28771738 Review.
-
Drug-induced tinnitus and other hearing disorders.Drug Saf. 1996 Mar;14(3):198-212. doi: 10.2165/00002018-199614030-00006. Drug Saf. 1996. PMID: 8934581 Review.
Cited by
-
A human model of Buruli ulcer: Provisional protocol for a Mycobacterium ulcerans controlled human infection study.Wellcome Open Res. 2024 Oct 21;9:488. doi: 10.12688/wellcomeopenres.22719.1. eCollection 2024. Wellcome Open Res. 2024. PMID: 39386965 Free PMC article.
-
Shifting the antibiotic rhetoric in children from 'just in case' to 'disclose the risk': Has the time come?J Assoc Med Microbiol Infect Dis Can. 2024 Mar 29;9(1):6-10. doi: 10.3138/jammi-2023-12-08. eCollection 2024 Mar. J Assoc Med Microbiol Infect Dis Can. 2024. PMID: 38567369 Free PMC article. No abstract available.
-
Breaking boundaries: the advancements in transdermal delivery of antibiotics.Drug Deliv. 2024 Dec;31(1):2304251. doi: 10.1080/10717544.2024.2304251. Epub 2024 Jan 19. Drug Deliv. 2024. PMID: 38241087 Free PMC article. Review.
-
Increased risk of hearing loss associated with macrolide use: a systematic review and meta-analysis.Sci Rep. 2024 Jan 2;14(1):183. doi: 10.1038/s41598-023-50774-1. Sci Rep. 2024. PMID: 38167873 Free PMC article.
-
Case Report: Omadacycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in an adolescent patient.Front Cell Infect Microbiol. 2023 Sep 29;13:1244398. doi: 10.3389/fcimb.2023.1244398. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37842004 Free PMC article.
References
-
- Van Boeckel TP, Gandra S, Ashok A. et al.Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742–50. - PubMed
-
- Stichting Werkgroep AntibioticaBeleid. Comm-acq pneumonie - Chlamydia.https://adult.swabid.nl/nl/node/7408.
-
- Stichting Werkgroep AntibioticaBeleid. Chlamydia (incl. LGV).https://adult.swabid.nl/nl/node/8106.
-
- Stichting Werkgroep AntibioticaBeleid. Helicobacter pylori.https://adult.swabid.nl/nl/node/8049.
-
- Stichting Werkgroep AntibioticaBeleid. Gastroenteritis - Campylobacter spp.https://adult.swabid.nl/nl/node/7950.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
